News & Articles nephropathy ChemoCentryx Announces Completion of Target Enrollment of CCX140 Phase II Clinical Trial in Diabetic Nephropathy MOUNTAIN VIEW, Calif. -- ChemoCentryx, Inc. announced that it has completed the target enrollment of 270 patients in a Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine ... June 19, 2013 - GlobeNewswire via Yahoo! Finance